drug administered intravenous infusion 60 hours zulresso cause dizziness drowsiness sedation fainting fda requiring women treated inpatient facility hospital monitored clinical trials enrolled 200 women postpartum depression zulresso demonstrated reduction ham d total score common measure depression severity average 17 points compared 13 points placebo statistically significant benefit favoring zulresso continued 30 days treatment stopped 60 hours zulresso proprietary formulation neurologic steroid allopregnanolone works modulating neurotransmitters brain called gaba receptors brain main inhibitory system differently currently approved anti seizure medications sage charge $ 34,000 single treatment course zulresso discounts rebates added expense short hospital stay jonas sage ceo expects wide